Biogen Inc
BIIBHealthcare|Drug Manufacturers - General|USA
$172.34
-5.00 (-2.82%)
DCF (FCF)
$259.03
Tangible Book
$17.62
Graham Number
$77.87
Earnings Power
$149.79
Clinical Trials (515)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04468659 AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid | Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease | P3 | Active | 1,400 | RCT, Double-blind | Lecanemab, Placebo |
| NCT03887455 A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | Early Alzheimer's Disease | P3 | Active | 1,906 | RCT, Double-blind | Lecanemab IV, Placebo, Lecanemab SC |
| NCT06935357 A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | Immunoglobulin A Nephropathy (IgAN) | P3 | Recruiting | 454 | RCT, Double-blind | Felzartamab, Placebo |
| NCT04895241 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic | P3 | Active | 548 | RCT, Double-blind | Litifilimab, Placebo |
| NCT04856982 A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | P3 | Active | 158 | RCT, Double-blind | Tofersen, Placebo |
| NCT06685757 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) | Antibody-mediated Rejection | P3 | Recruiting | 120 | RCT, Double-blind | Felzartamab, Placebo |
| NCT04729907 A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD) | Muscular Atrophy, Spinal | P3 | Active | 115 | Double-blind | Nusinersen |
| NCT04961567 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic | P3 | Active | 562 | RCT, Double-blind | Litifilimab, Placebo |
| NCT03958877 A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | P3 | Active | 152 | RCT, Open-label | BIIB017 (peginterferon beta-1a), Interferon beta type 1a |
| NCT05067790 A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) | Spinal Muscular Atrophy | P3 | Active | 45 | Open-label | Nusinersen |
| NCT06953583 A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE) | Friedreich Ataxia | P3 | Recruiting | 255 | RCT, Double-blind | Omaveloxolone, Placebo |
| NCT06602193 Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | Parkinson Disease | P2 | Recruiting | 50 | RCT, Double-blind | BIIB122 225 mg |
| NCT05348785 A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 | Parkinson Disease | P2 | Active | 650 | RCT, Double-blind | BIIB122, BIIB122-Matching Placebo |
| NCT07219043 A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation | Microvascular Inflammation | P2 | Recruiting | 81 | RCT, Double-blind | Felzartamab, Placebo |
| NCT05418010 Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS) | Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination | P2 | Recruiting | 40 | RCT, Double-blind | Tyruko Injectable Product, Placebo |
| NCT06555419 A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK) | Muscular Atrophy, Spinal | P1 | Recruiting | 58 | Open-label | Nusinersen |
| NCT06064929 A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old | Lupus Nephritis | P1 | Active | 14 | Open-label | Felzartamab |
| NCT06054893 A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old | Friedreich Ataxia | P1 | Recruiting | 35 | Open-label | Omaveloxolone |
| NCT07133828 A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old | Healthy Volunteer | P1 | Recruiting | 78 | RCT, Double-blind | BIIB142, BIIB142-Matching Placebo |
| NCT07297199 A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55 | Healthy Volunteer | P1 | Recruiting | 70 | RCT, Open-label | Omaveloxolone |
| NCT05575011 A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec | Healthy Volunteer, Muscular Atrophy, Spinal | P1 | Active | 62 | RCT, Double-blind | BIIB115, BIIB115-Matching Placebo |
| NCT05866419 Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy | Spinal Muscular Atrophy, Spine Deformity | N/A | Recruiting | 90 | Open-label | — |
| NCT01848028 PsoBest - The German Psoriasis Registry | Psoriasis, Psoriatic-arthritis | Recruiting | 3,500 | — | — | |
| NCT03047369 The Myelin Disorders Biorepository Project | Leukodystrophy, White Matter Disease | Recruiting | 12,000 | — | — | |
| NCT06628687 A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies | Friedreich Ataxia | Recruiting | 20 | — | Omaveloxolone | |
| NCT06053749 An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden | Multiple Sclerosis (MS) | Active | 4 | — | Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited), Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG), Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V), MS disease modifying drugs (MSDMDs) | |
| NCT05042921 Pediatric Spinal Muscular Atrophy (SMA) China Registry | Muscular Atrophy, Spinal | Active | 600 | — | — | |
| NCT05925049 A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis | Active | 400 | — | Natalizumab | |
| NCT05767736 A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS) | Multiple Sclerosis | Active | 10,500 | — | Diroximel Fumarate, Dimethyl Fumarate, Disease-Modifying Therapies (DMTs) | |
| NCT05789758 A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies | Muscular Atrophy, Spinal | Recruiting | 20 | — | — | |
| NCT07398469 A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone | Postpartum Depression | Recruiting | 200 | — | Zuranolone | |
| NCT07400198 Gait and Bone Health in SMA | Spinal Muscular Atrophy Type 3, Ambulatory Spinal Muscular Atrophy | Recruiting | 22 | — | — | |
| NCT05618379 Adult Spinal Muscular Atrophy (SMA) China Registry | Muscular Atrophy, Spinal | Active | 200 | — | — | |
| NCT04292574 UK SMA Patient Registry | Spinal Muscular Atrophy, SMA | Recruiting | 800 | — | — | |
| NCT04317794 Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium) | Muscular Atrophy, Spinal | Active | 74 | — | Nusinersen Sodium Injection | |
| NCT05017142 Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) | Optic Neuritis, Transverse Myelitis | Recruiting | 500 | — | — | |
| NCT05658497 Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) | Multiple Sclerosis | Recruiting | 908 | — | Diroximel Fumarate, Avonex, Tysabri, Dimethyl Fumarate | |
| NCT06978985 Adult SMA Research and Clinical Hub | Spinal Muscular Atrophy (SMA) | Recruiting | 600 | — | Risdiplam, Nusinersen Injectable Product | |
| NCT00498368 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy | IgA Nephropathy | P4 | Completed | 34 | RCT, Open-label | Intravenous Rituximab, ACE/ARB |
| NCT04048577 A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | P4 | Unknown | 10 | Open-label | Dosing Interruption of Natalizumab |
| NCT03424733 Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects | Multiple Sclerosis | P4 | Unknown | 50 | Open-label | Plegridy, Prednisone, Tylenol Pill |
| NCT00168753 Community Based Trial for AMEVIVE® | Moderate to Severe Chronic Plaque Psoriasis | P4 | Completed | 114 | Open-label | Alefacept |
| NCT02343159 Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients. | Multiple Sclerosis | P4 | Terminated | 84 | RCT, Open-label | dimethyl fumarate |
| NCT00168766 Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS | Relapsing-remitting Multiple Sclerosis | P4 | Completed | 345 | RCT, Double-blind | Interferon-beta-1a (Avonex) plus methylprednisolone |
| NCT00037102 Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis | Multiple Sclerosis | P4 | Completed | 16 | Open-label | interferon beta 1a, methotrexate |
| NCT00574041 How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose | Relapsing Remitting Multiple Sclerosis | P4 | Terminated | 19 | RCT, Single-blind | Interferon beta-1a |
| NCT01480076 Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis | Multiple Sclerosis | P4 | Completed | 901 | Open-label | Fampridine |
| NCT00179478 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis | Multiple Sclerosis, Optic Neuritis | P4 | Completed | 155 | RCT, Single-blind | interferon beta 1a 30 ug IM once weekly |
| NCT00871780 A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients | Relapsing Remitting Multiple Sclerosis (RRMS) | P4 | Completed | 224 | Open-label | BG00002 (natalizumab) |
| NCT01873417 Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States | Relapsing Forms of Multiple Sclerosis | P4 | Completed | 237 | Open-label | BG00012 (DMF) |
| NCT03091569 Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy | Relapsing-Remitting Multiple Sclerosis | P4 | Completed | 23 | RCT, Double-blind | — |
| NCT00492466 Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies | Relapsing-Remitting Multiple Sclerosis | P4 | Completed | 14 | Open-label | Interferon-beta-1a, methylprednisolone |
| NCT05177718 Natalizumab and Chronic Inflammation | Multiple Sclerosis | P4 | Terminated | 1 | Open-label | Natalizumab 300 MG in 15 ML Injection |
| NCT02143167 Resistance Training and Amino Pyridine in Multiple Sclerosis | Multiple Sclerosis | P4 | Completed | 40 | RCT, Double-blind | SR-fampridine, Placebo |
| NCT00744679 A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State | Multiple Sclerosis | P4 | Completed | 20 | Open-label | Natalizumab |
| NCT02739542 Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS) | Multiple Sclerosis (MS) | P4 | Completed | 87 | RCT, Double-blind | Tecfidera, Placebo |
| NCT00493116 Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta | Relapsing-Remitting Multiple Sclerosis | P4 | Completed | 20 | Open-label | Interferon-beta-1a, methylprednisolone |
| NCT03092544 Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients | Multiple Sclerosis | P4 | Unknown | 57 | Open-label | dimethyl fumarate |
| NCT00246324 Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis | Multiple Sclerosis | P4 | Completed | 16 | Open-label | Interferon beta 1a, oral doxycycline |
| NCT01656148 FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra | Multiple Sclerosis | P4 | Completed | 108 | RCT, Double-blind | Fampridine-SR |
| NCT00090038 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | P4 | Completed | 168 | Open-label | rituximab |
| NCT05532163 A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis, Relapsing-Remitting | P4 | Terminated | 1 | Open-label | Natalizumab |
| NCT02587065 Plegridy Satisfaction Study in Participants | Relapsing-Remitting Multiple Sclerosis (RRMS) | P4 | Completed | 193 | Open-label | peginterferon beta-1a |
| NCT00536120 The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis | P4 | Completed | 60 | RCT, Open-label | BG00002 (natalizumab), keyhole limpet hemocyanin (KLH), tetanus diphtheria toxoid vaccine (Td) |
| NCT01591551 NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness | Multiple Sclerosis, Relapsing-Remitting | P4 | Completed | 37 | Open-label | Natalizumab (Tysabri) |
| NCT00112034 AVONEX® Combination Trial - "ACT" | Multiple Sclerosis, Relapsing-Remitting | P4 | Completed | 350 | RCT, Double-blind | Methotrexate, IV methylprednisolone |
| NCT00794807 Safety and Tolerability of Repeat Courses of IM Alefacept | Chronic Plaque Psoriasis | P4 | Completed | 20 | Open-label | Alefacept |
| NCT01930708 A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes | Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | P4 | Completed | 1,114 | Open-label | dimethyl fumarate |
| NCT05658484 A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China | Multiple Sclerosis | P4 | Completed | 60 | Open-label | Dimethyl fumarate |
| NCT02472938 Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | P4 | Withdrawn | — | RCT, Double-blind | dimethyl fumarate |
| NCT02410278 Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera | Multiple Sclerosis | P4 | Completed | 102 | RCT, Double-blind | dimethyl fumarate, montelukast, Placebo |
| NCT00913666 Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers | Multiple Sclerosis | P4 | Completed | 121 | Single-blind | Interferon beta-1a (Avonex) |
| NCT03177083 Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy | Relapsing Remitting Multiple Sclerosis | P4 | Completed | 80 | RCT, Open-label | peginterferon beta-1a, interferon beta-1a, interferon beta-1b |
| NCT02471560 Tecfidera and the Gut Microbiota | Multiple Sclerosis, Relapsing-Remitting | P4 | Completed | 36 | Open-label | dimethyl fumarate, injectable MS DMT |
| NCT02142205 Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) | Relapsing-Remitting Multiple Sclerosis | P4 | Completed | 100 | Open-label | BG00002 |
| NCT00774202 Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP | Immune Thrombocytopenic Purpura | P2P3 | Completed | 17 | RCT, Single-blind | Rituxan, Cyclophosphamide, Vincristine, Prednisone, Higher Dose of Rituximab |
| NCT00660959 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia | Hyponatremia With Normal Extracellular Fluid Volume | P3 | Completed | 106 | RCT, Double-blind | lixivaptan, placebo |
| NCT00090051 FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients | Chronic Lymphocytic Leukemia | P3 | Completed | 552 | RCT, Open-label | Rituximab, Fludarabine Phosphate, Cyclophosphamide |
| NCT00692172 Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis | Psoriasis | P3 | Completed | 175 | Open-label | Alefacept |
| NCT00578695 THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation | Hyponatremia | P3 | Completed | 652 | RCT, Double-blind | lixivaptan, Placebo |
| NCT00673556 A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate | Chronic Plaque Psoriasis | P3 | Completed | 195 | RCT, Double-blind | alefacept, placebo |
| NCT03070119 Long-Term Evaluation of BIIB067 (Tofersen) | ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation | P3 | Completed | 139 | Open-label | Tofersen |
| NCT03093324 A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 | Relapsing Remitting Multiple Sclerosis | P3 | Completed | 506 | RCT, Double-blind | ALKS 8700, Dimethyl Fumarate |
| NCT00443651 A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis | Rheumatoid Arthritis | P3 | Completed | 578 | Open-label | Rituximab, Anti-inflammatory drugs |
| NCT00876798 A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia | Euvolemic Hyponatremia | P3 | Completed | 206 | RCT, Double-blind | Lixivaptan, Placebo |
| NCT05418673 A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale | Parkinson Disease | P3 | Terminated | 7 | RCT, Double-blind | BIIB122, BIIB122-Matching Placebo |
| NCT00876876 International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia | Hypervolemic Hyponatremia | P3 | Withdrawn | 300 | RCT, Open-label | Lixivaptan |
| NCT00674063 A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis | P3 | Completed | 78 | RCT, Double-blind | alefacept |
| NCT02956486 A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease | Alzheimer's Disease | P3 | Terminated | 2,212 | RCT, Double-blind | Elenbecestat, Placebo |
| NCT02634307 A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 | Multiple Sclerosis | P3 | Completed | 1,057 | Open-label | ALKS 8700 |
| NCT02623699 An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P3 | Completed | 176 | RCT, Double-blind | Tofersen, Placebo |
| NCT00297232 Natalizumab (Tysabri) Re-Initiation of Dosing | Relapsing-Remitting Multiple Sclerosis | P3 | Terminated | 1,094 | Open-label | Natalizumab |
| NCT00168740 Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) | Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma | P3 | Completed | 150 | Open-label | rituximab |
| NCT00306592 Natalizumab Re-Initiation of Dosing | Multiple Sclerosis, Relapsing-Remitting | P3 | Completed | 404 | Open-label | BG00002 (natalizumab) |
| NCT01917019 A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis | Multiple Sclerosis, Remittent Progressive, Multiple Sclerosis, Primary Progressive | P3 | Completed | 101 | RCT, Double-blind | Placebo, BIIB041 (fampridine) |
| NCT01337427 Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | P3 | Withdrawn | — | RCT, Double-blind | BIIB017 |
| NCT03689972 A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration | Multiple Sclerosis, Relapsing-Remitting | P3 | Completed | 585 | RCT, Open-label | Natalizumab, Natalizumab |
| NCT00032786 Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease | Crohn's Disease | P3 | Completed | — | RCT, Double-blind | natalizumab |
| NCT00363636 A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) | Lymphoma, Non-Hodgkin's | P3 | Terminated | 340 | RCT, Double-blind | Galiximab in combination with rituximab, Rituximab in combination with placebo |
| NCT00027300 Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | P3 | Completed | 900 | RCT, Double-blind | Natalizumab, Placebo |
| NCT03918447 A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON | Autosomal Dominant Polycystic Kidney, ADPKD | P3 | Terminated | 667 | RCT, Double-blind | Bardoxolone methyl oral capsule, Placebo oral capsule |
| NCT00242268 A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | P3 | Unknown | 30 | RCT, Double-blind | Simvastatin |
| NCT02097745 A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies | Rheumatoid Arthritis | P3 | Completed | 341 | Open-label | methotrexate, rituximab [MabThera/Rituxan] |
| NCT00451451 Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | P3 | Completed | 1,417 | RCT, Double-blind | BG00012, Placebo, Glatiramer Acetate |
| NCT02477800 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | Alzheimer's Disease | P3 | Terminated | 1,653 | RCT, Double-blind | Aducanumab (BIIB037), Aducanumab (BIIB037), Placebo |
| NCT04089566 Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy | Muscular Atrophy, Spinal | P3 | Completed | 145 | RCT, Double-blind | Nusinersen |
| NCT02657356 Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST | Connective Tissue Disease-Associated Pulmonary Arterial Hypertension | P3 | Terminated | 202 | RCT, Double-blind | Placebo capsules, Bardoxolone methyl capsules |
| NCT00828204 Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects | Multiple Sclerosis | P3 | Completed | 95 | Open-label | BG9418 (interferon beta-1a) |
| NCT00030966 Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | P3 | Completed | 1,200 | RCT, Double-blind | Natalizumab, Placebo |
| NCT01939002 Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) | Relapsing Multiple Sclerosis | P3 | Completed | 251 | RCT, Open-label | BIIB017, naproxen |
| NCT01235221 Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials. | Multiple Sclerosis | P3 | Completed | 38 | Open-label | BIIB041 (Fampridine-SR) |
| NCT00384150 Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) | Lymphoma, Non-Hodgkin's | P3 | Terminated | 16 | Open-label | galiximab in combination with rituximab |
| NCT02430532 BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Secondary Progressive | P3 | Terminated | 58 | RCT, Double-blind | dimethyl fumarate |
| NCT01440101 Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis | P2P3 | Completed | 106 | RCT, Double-blind | Natalizumab (BG00002), Placebo |
| NCT03019185 A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL | Alport Syndrome | P2P3 | Completed | 187 | RCT, Double-blind | Placebo Oral Capsule, Bardoxolone Methyl |
| NCT07444450 A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec | Muscular Atrophy, Spinal | P3 | Not Yet Recruiting | 42 | RCT, Double-blind | Salanersen |
| NCT07483632 A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) | Relapsing Forms of Multiple Sclerosis | P3 | Not Yet Recruiting | 185 | RCT, Double-blind | Diroximel Fumarate, Dimethyl Fumarate, Fingolimod, Placebo matching DRF, Placebo matching DMF, Placebo matching fingolimod |
| NCT05310071 A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease | Alzheimer's Disease | P3 | Terminated | 1,027 | RCT, Double-blind | Aducanumab, Placebo |
| NCT00709865 Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency | Renal Insufficiency, Congestive Heart Failure | P3 | Completed | 420 | RCT, Double-blind | tonapofylline, Placebo |
| NCT02193074 A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy | Spinal Muscular Atrophy | P3 | Terminated | 122 | RCT, Double-blind | nusinersen |
| NCT00057343 Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | P3 | Terminated | 400 | RCT, Open-label | Zevalin (ibritumomab tiuxetan), Rituxan (rituximab) |
| NCT00906399 Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | P3 | Completed | 1,516 | RCT, Double-blind | BIIB017 (peginterferon beta-1a), Placebo |
| NCT01181115 Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) | Multiple Sclerosis | P3 | Completed | 60 | Open-label | Avonex |
| NCT00276172 Open-Label Natalizumab Safety Extension Study | Multiple Sclerosis | P3 | Completed | 1,615 | Open-label | Natalizumab |
| NCT02219932 Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis | Multiple Sclerosis | P3 | Completed | 646 | RCT, Double-blind | fampridine, Placebo |
| NCT00223301 Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis | Multiple Sclerosis | P2P3 | Completed | 24 | RCT, Double-blind | Mycophenolate Mofetil (cellcept) |
| NCT01838668 An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) | Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | P3 | Completed | 225 | RCT, Double-blind | Placebo, dimethyl fumarate |
| NCT00697996 Rituximab for Pediatric Renal Transplant Rejection | Kidney Transplantation | P2P3 | Completed | 20 | RCT, Open-label | Rituximab for transplant rejection |
| NCT03870763 Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants | Multiple Sclerosis, Relapsing-Remitting | P3 | Terminated | 11 | RCT, Double-blind | Dimethyl Fumarate, Peginterferon Beta-1a, Placebo |
| NCT03771664 A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia | Major Depressive Disorder, Insomnia | P3 | Terminated | 87 | RCT, Double-blind | SAGE-217, Placebo |
| NCT06044337 A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | P3 | By Invite | 322 | Open-label | BIIB059 (litifilimab) |
| NCT00032799 Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease | Crohn's Disease | P3 | Completed | 905 | RCT, Double-blind | natalizumab |
| NCT03672175 A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder | Major Depressive Disorder | P3 | Completed | 581 | RCT, Double-blind | SAGE-217, Placebo |
| NCT00078611 A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease | Crohn's Disease | P3 | Completed | 462 | RCT, Double-blind | natalizumab |
| NCT01332019 Long-Term Safety and Efficacy Study of Peginterferon Beta-1a | Relapsing Multiple Sclerosis | P3 | Completed | 1,077 | Open-label | peginterferon beta-1a |
| NCT00420212 Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | P3 | Completed | 1,234 | RCT, Double-blind | BG00012, Placebo |
| NCT01568112 Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate | Healthy | P3 | Completed | 173 | RCT, Double-blind | BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo |
| NCT02594124 A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies | Spinal Muscular Atrophy | P3 | Completed | 292 | Open-label | nusinersen |
| NCT01351675 Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes | Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2 | P3 | Terminated | 2,185 | RCT, Double-blind | Placebo, Bardoxolone Methyl: 20 mg |
| NCT02525874 Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). | Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis | P3 | Completed | 218 | Open-label | dimethyl fumarate |
| NCT00468546 A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy | Rheumatoid Arthritis | P3 | Completed | 520 | RCT, Double-blind | MabThera/Rituxan, Methotrexate |
| NCT07444476 A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam | Spinal Muscular Atrophy | P3 | Not Yet Recruiting | 90 | Open-label | Salanersen |
| NCT04442490 A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD) | Depressive Disorder, Major | P3 | Completed | 543 | RCT, Double-blind | SAGE-217, Placebo |
| NCT01064401 Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | P3 | Completed | 1,841 | RCT, Double-blind | BIIB019 (Daclizumab High Yield Process), Interferon beta-1a Placebo, Interferon beta-1a, Daclizumab High Yield Process Placebo |
| NCT01622088 Phase 3 Extension Study of Dexpramipexole in ALS | Amyotrophic Lateral Sclerosis | P3 | Terminated | 616 | Open-label | Dexpramipexole |
| NCT01462318 An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | P3 | Completed | 133 | Open-label | Midazolam, S-warfarin, Omeprazole, Dextromethorphan, BIIB019 (Daclizumab) |
| NCT02484547 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | Alzheimer's Disease | P3 | Terminated | 1,643 | RCT, Double-blind | Aducanumab (BIIB037), Aducanumab (BIIB037), Placebo |
| NCT00784836 Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients | Multiple Sclerosis | P3 | Terminated | 3 | Open-label | BG9418 (interferon beta 1-a) |
| NCT07444489 A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) | Antibody-mediated Rejection | P3 | Not Yet Recruiting | 120 | Open-label | Felzartamab |
| NCT05352919 An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | Systemic Lupus Erythematosus (SLE) | P3 | By Invite | 864 | RCT, Double-blind | Litifilimab, Litifilimab-matching placebo |
| NCT02292537 A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) | Spinal Muscular Atrophy | P3 | Completed | 126 | RCT, Double-blind | Nusinersen |
| NCT03749447 An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) | Chronic Kidney Diseases, Alport Syndrome | P3 | Terminated | 270 | Open-label | Bardoxolone methyl |
| NCT04241068 A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 | Alzheimer's Disease | P3 | Terminated | 1,696 | Open-label | Aducanumab |
| NCT04476030 A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder | Depressive Disorder, Major | P3 | Completed | 440 | RCT, Double-blind | SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine |
| NCT00424749 Rituxan in Churg Strauss Syndrome With Renal Involvement | Churg-Strauss Syndrome | P2 | Terminated | 4 | Open-label | Rituximab, Prednisone |
| NCT00588822 Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance | Precancerous Condition | P2 | Terminated | 21 | Open-label | Rituximab |
| NCT00298272 Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Terminated | 54 | RCT, Double-blind | IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone |
| NCT00290511 Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma | Lymphoma | P2 | Completed | 49 | Open-label | Fludarabine, Mitoxantrone, Rituximab, Zevalin, Dexamethasone |
| NCT00280241 Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | P2 | Completed | 65 | Open-label | Fludarabine, Cyclophosphamide, Rituximab |
| NCT00659412 A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis | Psoriatic Arthritis | P2 | Completed | 185 | RCT, Double-blind | Alefacept, Methotrexate, Placebo |
| NCT01767311 A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease | Alzheimer's Disease | P2 | Completed | 856 | RCT, Double-blind | Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Placebo, Lecanemab 10 mg/kg |
| NCT00106184 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) | Myositis, Dermatomyositis | P2 | Completed | 200 | RCT, Double-blind | Rituximab, Placebo |
| NCT00642655 Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation | Kidney Transplant | P1P2 | Completed | 20 | Open-label | IVIG and Rituximab |
| NCT02322021 Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease | Alzheimer Disease, Dementia, Alzheimer Type | P2 | Terminated | 70 | RCT, Double-blind | E2609, Placebo |
| NCT00117156 Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma | Lymphoma, Non-Hodgkin, MALT Lymphoma | P2 | Completed | 26 | Open-label | Fludarabine, Rituximab |
| NCT01713738 Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP) | Idiopathic Thrombocytopenic Purpura (ITP), Immune Thrombocytopenic Purpura (ITP) | P1P2 | Completed | 36 | Open-label | rituximab |
| NCT00379587 Rituximab for Prevention of Chronic GVHD | Hematological Malignancies | P1P2 | Completed | 65 | Open-label | Rituximab, 375 mg/m2 RRituximab |
| NCT00584935 Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid | Ocular Cicatricial Pemphigoid | P1P2 | Completed | 3 | Open-label | Rituximab |
| NCT00103558 Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia | P1P2 | Completed | 31 | Open-label | Lumiliximab with FCR |
| NCT02855411 A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | Cognitive Impairment Associated With Schizophrenia (CIAS) | P2 | Terminated | 35 | RCT, Double-blind | PF-04958242, placebo |
| NCT01405820 Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) | Relapsing-Remitting Multiple Sclerosis | P2 | Completed | 290 | RCT, Double-blind | natalizumab IV, natalizumab SC, IV Placebo, SC Placebo |
| NCT01181089 Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) | Secondary Progressive Multiple Sclerosis | P1P2 | Withdrawn | — | RCT, Double-blind | Placebo, Baminercept |
| NCT00801060 Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia | P2 | Terminated | 40 | RCT, Open-label | Lumiliximab + FCR, FCR |
| NCT03000530 A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder | Major Depression | P2 | Completed | 102 | RCT, Double-blind | SAGE-217, Placebo |
| NCT00135733 A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus | Lichen Planus | P2 | Terminated | 13 | RCT, Double-blind | Amevive (Alefacept), Placebo |
| NCT00097760 Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | P2 | Completed | 110 | RCT, Double-blind | Natalizumab, Natalizumab, Placebo |
| NCT05764122 A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well | Ischemic Stroke | P2 | Withdrawn | — | RCT, Double-blind | BIIB131, Placebo |
| NCT05895552 A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathic Pain | P2 | Terminated | 209 | RCT, Double-blind | RTA 901, RTA 901-Matching Placebo |
| NCT00538343 RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases | Brain Metastases | P2 | Terminated | 14 | Open-label | berubicin hydrochloride (RTA 744) |
| NCT03352557 Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | Alzheimer's Disease | P2 | Terminated | 654 | RCT, Double-blind | BIIB092, Placebo |
| NCT03507686 A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 | Choroideremia | P2 | Completed | 66 | Open-label | BIIB111 |
| NCT00493454 Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas | Lymphoma | P2 | Terminated | 6 | Open-label | Zevalin, Rituximab, ^111 In Ibritumomab Tiuxetan |
| NCT01416155 Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | P2 | Completed | 97 | Open-label | natalizumab |
| NCT02462759 A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA). | Spinal Muscular Atrophy | P2 | Terminated | 21 | RCT, Double-blind | Nusinersen |
| NCT03116113 A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 | X-Linked Retinitis Pigmentosa | P1P2 | Completed | 50 | RCT, Double-blind | BIIB112 |
| NCT00635193 Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | Ovarian Cancer, Primary Peritoneal Cancer | P1P2 | Completed | 138 | RCT, Open-label | M200 (Volociximab), Liposomal Doxorubicin, M200 (Volociximab), M200 (Volociximab) |
| NCT01071083 Treatment Interruption of Natalizumab | Relapsing Remitting Multiple Sclerosis | P2 | Completed | 175 | RCT, Double-blind | natalizumab, interferon beta 1-a, methylprednisolone, glatiramer acetate |
| NCT00391066 Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia | P2 | Terminated | 627 | RCT, Open-label | FCR + Lumiliximab, FCR |
| NCT02255435 A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia | Friedreich Ataxia | P2 | Completed | 172 | RCT, Double-blind | Omaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg, Omaveloxolone Capsules, 10 mg, Placebo, Omaveloxolone Capsules, 20 mg, Omaveloxolone Capsules, 40 mg, Omaveloxolone Capsules, 80 mg, Omaveloxolone Capsules, 160 mg, Omaveloxolone Capsules, 300 mg, Omaveloxolone Capsules, 150 mg |
| NCT00442780 Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease | Parkinson's Disease | P2 | Completed | 36 | RCT, Double-blind | BIIB014, Placebo |
| NCT04079088 Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) | Relapsing Multiple Sclerosis | P2 | Withdrawn | — | RCT, Double-blind | Placebo, BIIB061, Interferon-beta1, Glatiramer acetate |
| NCT00831649 A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201 | Rheumatoid Arthritis | P2 | Terminated | — | Open-label | natalizumab |
| NCT02128113 RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD | Corneal Endothelial Cell Loss, Ocular Pain | P2 | Completed | 307 | RCT, Double-blind | Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1% |
| NCT00912860 Immunogenicity and Safety Study of Serum-Free Avonex | Multiple Sclerosis | P2 | Completed | 155 | Open-label | Interferon beta-1a |
| NCT00664027 Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy | Diabetic Nephropathy | P2 | Completed | 80 | RCT, Open-label | RTA 402 (Bardoxolone Methyl) |
| NCT00493467 Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas | Lymphoma | P2 | Completed | 31 | Open-label | Ibritumomab Tiuxetan (Zevalin), Rituximab |
| NCT02142192 Natalizumab Subcutaneous Immunogenicity and Safety Study | Relapsing Multiple Sclerosis | P2 | Terminated | 2 | Open-label | natalizumab |
| NCT02133924 Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease | Acute Graft Versus Host Disease | P2 | Completed | 76 | Open-label | natalizumab, steroids |
| NCT02957617 Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074 | Neuropathic Pain From Lumbosacral Radiculopathy | P2 | Terminated | 302 | Open-label | BIIB074 |
| NCT01930890 BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis | Lupus Nephritis | P2 | Terminated | 87 | RCT, Double-blind | BIIB023, mycophenolate mofetil, oral corticosteroids |
| NCT00301002 Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis | Psoriasis, Palmoplantaris Pustulosis | P2 | Completed | 15 | Open-label | Alefacept |
| NCT03366337 A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX | IgA Nephropathy, CKD Associated With Type 1 Diabetes | P2 | Completed | 103 | Open-label | Bardoxolone methyl capsules |
| NCT00523328 BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861) | Rheumatoid Arthritis | P2 | Terminated | 72 | Open-label | BG9924 |
| NCT00369395 A Study of Volociximab in Metastatic Melanoma | Stage IV Melanoma | P2 | Terminated | 19 | Open-label | volociximab |
| NCT00102024 Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma | Colorectal Cancer, Metastases | P1P2 | Terminated | 30 | Open-label | Unconjugated IDEC-159, 111In-IDEC-159, 90Y-IDEC-159 |
| NCT01597297 Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. | Multiple Sclerosis | P2 | Completed | 132 | RCT, Double-blind | BIIB041 (PR Fampridine) |
| NCT00292422 Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Completed | 50 | RCT, Double-blind | BG9924 |
| NCT02142959 RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE | Breast Cancer | P2 | Completed | 187 | RCT, Double-blind | Omaveloxolone Lotion 0.5%, Omaveloxolone Lotion 3%, Vehicle Lotion |
| NCT01499355 BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis | Lupus Nephritis | P2 | Terminated | 276 | RCT, Double-blind | BIIB023, Placebo, mycophenolate mofetil, oral corticosteroids |
| NCT00516893 Natalizumab High Titer Immunogenicity and Safety | Multiple Sclerosis | P2 | Completed | 113 | Open-label | BG00002-E (natalizumab high titer) |
| NCT00193440 Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma | Non-Hodgkins Lymphoma | P2 | Completed | 40 | Open-label | Rituximab, CHOP, CVP, Ibritumomab Tiuxetan |
| NCT00390221 Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | P2 | Completed | 621 | RCT, Double-blind | BIIB019 (Daclizumab High Yield Process), Placebo |
| NCT01703988 An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy | Spinal Muscular Atrophy | P1P2 | Completed | 34 | Open-label | Nusinersen |
| NCT01561027 Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy | Lumbosacral Radiculopathy | P2 | Completed | 82 | RCT, Double-blind | CNV1014802, Placebo |
| NCT02657915 Long-Term Assessment of Remyelinating Therapy | Acute Optic Neuritis | P2 | Completed | 52 | RCT, Double-blind | Placebo, BIIB033 100mg/Kg |
| NCT00438607 Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease | Parkinson's Disease | P2 | Completed | 83 | RCT, Double-blind | BIIB014, Placebo |
| NCT00550849 Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction | Liver Disease | P1P2 | Terminated | 16 | RCT, Double-blind | RTA 402, RTA 402, RTA 402 |
| NCT00616434 A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis | Active Ulcerative Colitis | P2 | Completed | 123 | RCT, Double-blind | BG9418 (Interferon beta-1a), Placebo |
| NCT02935608 Study to Evaluate the Efficacy and Safety of BIIB074 in Neuropathic Pain From Lumbosacral Radiculopathy | Lumbosacral Radiculopathy | P2 | Completed | 502 | RCT, Double-blind | BIIB074, Placebo |
| NCT00451815 BIIB014 Phase 2a Monotherapy | Parkinson's Disease | P2 | Withdrawn | — | RCT | active drug (BIIB014) at 10, 30, 100, or 300 mg once daily., placebo |
| NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) | Relapsing Forms of Multiple Sclerosis | P2 | Completed | 127 | RCT, Double-blind | BIIB091, DRF, Placebo |
| NCT03639987 A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities | Cognitive Dysfunction, Alzheimer's Disease | P2 | Terminated | 52 | RCT, Double-blind | Aducanumab, Placebo |
| NCT05021484 Felzartamab in Late Antibody-Mediated Rejection | Antibody-mediated Rejection | P2 | Completed | 22 | RCT, Double-blind | Felzartamab, Placebo |
| NCT04733040 Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE) | Glomerulonephritis, Membranous Nephropathy | P2 | Completed | 24 | RCT, Open-label | MOR202 |
| NCT00055367 Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease | Crohn's Disease | P2 | Completed | 30 | Open-label | natalizumab |
| NCT03339336 Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy | Small Fiber Neuropathy, Diabetes Mellitus | P2 | Terminated | 265 | RCT, Double-blind | BIIB074, Placebo |
| NCT05173012 Study to Evaluate SAGE-324 in Participants With Essential Tremor | Essential Tremor | P2 | Completed | 146 | RCT, Double-blind | SAGE-324, SAGE-324 Matched Placebo |
| NCT01053936 Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease | Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2 | P2 | Completed | 129 | RCT, Open-label | Bardoxolone methyl (amorphous dispersion) |
| NCT02917187 A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia | Primary Inherited Erythromelalgia | P2 | Completed | 8 | RCT, Double-blind | BIIB074, Placebo |
| NCT03283371 Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy | Epilepsy, Focal Seizures, Partial Seizures | P2 | Completed | 67 | RCT, Double-blind | Natalizumab |
| NCT01371305 STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis (IPF) | P2 | Completed | 41 | RCT, Double-blind | BG00011, Placebo |
| NCT00083759 Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate | Rheumatoid Arthritis | P2 | Terminated | 299 | RCT, Double-blind | natalizumab, placebo |
| NCT00031642 Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation | Lymphoma | P1P2 | Completed | 26 | Open-label | rituximab |
| NCT00038623 Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma | Lymphoma, Mantle-Cell | P2 | Completed | 35 | Open-label | Yttrium-ibritumomab (Zevalin), Rituximab |
| NCT02259231 RTA 408 Capsules in Patients With Melanoma - REVEAL | Melanoma, Unresectable (Stage III) Melanoma | P1P2 | Completed | 41 | Open-label | Omaveloxolone Capsules (2.5 mg/capsule), Ipilimumab (3 mg/kg), Nivolumab (240 mg), Omaveloxolone Capsules (10 mg/capsule), Omaveloxolone Capsules (50 mg/capsule) |
| NCT01540630 A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia | Trigeminal Neuralgia | P2 | Completed | 67 | RCT, Double-blind | CNV1014802, Placebo |
| NCT00055536 Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease | Crohn's Disease | P2 | Completed | 60 | RCT, Double-blind | natalizumab |
| NCT00664716 Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants | Rheumatoid Arthritis | P2 | Completed | 391 | RCT, Double-blind | Baminercept alfa 1, Placebo, Baminercept alfa 2, Baminercept alfa 3, Baminercept alfa 4, Baminercept alfa 5 |
| NCT00745316 Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency | Renal Insufficiency, Heart Failure | P2 | Terminated | 34 | RCT, Double-blind | Tonapofylline, Placebo |
| NCT00746941 Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) | Progressive Multifocal Leukoencephalopathy | P1P2 | Terminated | 37 | RCT, Single-blind | mefloquine |
| NCT04145440 Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) | Glomerulonephritis, Membranous, antiPLA2R Positive | P1P2 | Completed | 31 | Open-label | MOR202 |
| NCT00535314 Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma | Malignant Melanoma | P2 | Withdrawn | — | RCT, Open-label | RTA 402 Dose1, RTA 402 Dose2 |
| NCT00048555 Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | P1P2 | Completed | 90 | Open-label | IDEC-114 |
| NCT02959658 Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis | Primary Progressive Multiple Sclerosis | P2 | Completed | 54 | RCT, Double-blind | Dimethyl fumarate, Placebo |
| NCT01004081 Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding | Breast Cancer | P2 | Completed | 54 | RCT, Open-label | BIIB021, BIIB021, exemestane (Aromasin) |
| NCT00810836 Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Completed | 153 | RCT, Double-blind | BG00012, BG00012, placebo |
| NCT01721161 BIIB033 In Acute Optic Neuritis (AON) | Acute Optic Neuritis | P2 | Completed | 82 | RCT, Double-blind | BIIB033 (anti-LINGO-1 mAb), Placebo |
| NCT00811889 Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease | Chronic Kidney Disease, Type 2 Diabetes | P2 | Completed | 227 | RCT, Double-blind | Bardoxolone Methyl (RTA 402) |
| NCT02097849 Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. | Relapsing Forms of Multiple Sclerosis | P2 | Completed | 71 | Open-label | dimethyl fumarate, tetanus diphtheria toxoids vaccine, 23-valent pneumococcal polysaccharide vaccine, meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent), non-pegylated interferon |
| NCT03068468 Study of BIIB092 in Participants With Progressive Supranuclear Palsy | Supranuclear Palsy, Progressive | P2 | Terminated | 490 | RCT, Double-blind | BIIB092, Placebo |
| NCT00143806 Transitioning From Cyclosporine to Alefacept in Psoriasis | Psoriasis | P2 | Completed | 13 | Open-label | Transitioning patients from cyclosporine to alefacept |
| NCT01652937 BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs | Rheumatoid Arthritis | P2 | Withdrawn | — | RCT, Double-blind | BIIB057, Placebo |
| NCT04494256 A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation | Amyotrophic Lateral Sclerosis | P1P2 | Terminated | 99 | RCT, Double-blind | BIIB105, Placebo |
| NCT03222973 Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) | Multiple Sclerosis | P2 | Terminated | 263 | RCT, Double-blind | BIIB033 (opicinumab), Placebo |
| NCT02847598 Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus | P2 | Completed | 264 | RCT, Double-blind | BIIB059 (litifilimab), Placebo |
| NCT03000569 A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease | Parkinson Disease | P2 | Completed | 29 | Open-label | SAGE-217, Levodopa, Antiparkinsonian Agent(s) |
| NCT01655186 A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus | Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2 | P2 | Withdrawn | — | RCT, Double-blind | Bardoxolone Methyl, Placebo |
| NCT00119730 Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | Mantle Cell Lymphoma | P2 | Completed | 30 | Open-label | Fludarabine, Mitoxantrone, Rituximab, Zevalin |
| NCT03573505 An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | P2 | Terminated | 109 | RCT, Double-blind | BG00011, Placebo |
| NCT01538472 Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | Lymphoma | P1P2 | Completed | 40 | Open-label | Y Zevalin, In Zevalin, Rituxan, BCNU, VP -16, Ara-C, Melphalan, G-CSF |
| NCT03318523 Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease | Parkinson's Disease | P2 | Terminated | 357 | RCT, Double-blind | Placebo, BIIB054 |
| NCT00675428 Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | P1P2 | Terminated | 6 | RCT, Open-label | BG00002 (natalizumab) |
| NCT02386553 A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy | Spinal Muscular Atrophy | P2 | Completed | 25 | Open-label | Nusinersen |
| NCT00099489 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | P2 | Completed | 67 | RCT, Double-blind | Interferon Beta-1a |
| NCT00005592 Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Lymphoma | P2 | Completed | 23 | Open-label | 90-Y-ibritumomab tiuxetan, rituximab |
| NCT01156311 BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | P2 | Completed | 108 | Open-label | dimethyl fumarate |
| NCT02036970 Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT | Pulmonary Arterial Hypertension, Pulmonary Hypertension | P2 | Completed | 166 | RCT, Double-blind | Bardoxolone methyl, Placebo |
| NCT00376129 Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis | Atopic Dermatitis | P2 | Completed | 10 | RCT, Open-label | Alefacept |
| NCT03692910 A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode | Bipolar Disorder I, Bipolar Disorder II | P2 | Completed | 35 | Open-label | SAGE-217, Placebo |
| NCT00870740 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | P2 | Completed | 517 | RCT, Double-blind | BIIB019 (Daclizumab High Yield Process), Placebo |
| NCT05119790 A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects | Healthy Volunteers | P1 | Completed | 7 | Open-label | [14C] BIIB122 ([14C] DNL151) |
| NCT00675701 A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study | Healthy | P1 | Completed | 298 | RCT, Double-blind | placebo, lixivaptan, moxifloxacin |
| NCT05909644 An Open-label DDI Study of Omaveloxolone in Healthy Subjects | Healthy Adult Subjects | P1 | Completed | 20 | Open-label | Omaveloxolone, Efavirenz |
| NCT05005338 A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects | Healthy Volunteers | P1 | Completed | 8 | Open-label | BIIB122 (DNL151), [14C] BIIB122 ([14C] DNL151) |
| NCT00476515 Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor | Kidney Insufficiency | P1 | Withdrawn | — | Open-label | Rituximab |
| NCT02658916 Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 | Supranuclear Palsy, Progressive | P1 | Terminated | 47 | Open-label | BIIB092 |
| NCT06574828 A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants | Healthy Volunteer | P1 | Completed | 69 | RCT, Double-blind | BIIB091, Moxifloxacin, BIIB091-matched Placebo, Moxifloxacin-matched Placebo |
| NCT05229562 A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants | Healthy Volunteer | P1 | Completed | 84 | Open-label | BIIB122 |
| NCT04056689 Study to Evaluate DNL151 in Subjects With Parkinson's Disease | Parkinson's Disease | P1 | Completed | 36 | RCT, Double-blind | DNL151, Placebo |
| NCT01943513 A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers | Healthy | P1 | Completed | 34 | RCT, Double-blind | BIIB023, Placebo |
| NCT00961766 Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants | Sciatica | P1 | Completed | 48 | RCT, Single-blind | BG00010 (Neublastin), Placebo |
| NCT01780246 An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701) | Spinal Muscular Atrophy | P1 | Completed | 18 | Open-label | nusinersen |
| NCT02125578 A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers | Healthy | P1 | Completed | 69 | RCT, Double-blind | BIIB017 (PEGylated Interferon Beta-1a), Placebo |
| NCT01215084 A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers | Healthy | P1 | Completed | 36 | Open-label | BIIB041 (Fampridine-PR) |
| NCT03931590 A Human AME Study for Omaveloxolone | Healthy Male Subjects | P1 | Completed | 8 | Open-label | [14C]-Omaveloxolone |
| NCT04924140 A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 30 | RCT, Open-label | Aducanumab |
| NCT01518894 A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia | Schizophrenia | P1 | Completed | 30 | RCT, Double-blind | PF-04958242, PF-04958242, PF-04958242, Placebo |
| NCT00555724 Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors | Solid Tumors | P1 | Completed | 40 | Open-label | BIIB022 |
| NCT02829541 A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants | Systemic Lupos Erythematosus, SLE | P1 | Completed | 36 | RCT, Double-blind | BIIB068, Placebo |
| NCT00031083 Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | Glioblastoma Multiforme, Anaplastic Astrocytoma | P1 | Completed | 12 | Open-label | — |
| NCT03579030 Safety and PK/PD of RTA 1701 in Healthy Adults | Healthy | P1 | Completed | 90 | RCT, Double-blind | Placebo oral capsule, RTA 1701 capsules |
| NCT01119677 A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 120 | RCT, Double-blind | Avonex |
| NCT05618301 Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) | Sickle Cell Disease | P1 | Completed | 10 | Open-label | Motixafortide, Natalizumab |
| NCT05655507 Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD) | Major Depressive Disorder | P1 | Completed | 19 | Open-label | Zuranolone |
| NCT02029729 RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER | Metastatic or Incurable Non-small Cell Lung Cancer, Relapsed, Refractory Melanoma | P1 | Completed | 11 | Open-label | omaveloxolone |
| NCT03764488 A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults | Healthy Volunteers | P1 | Completed | 8 | Open-label | Tofersen, 99mTc-MAG3-BIIB067 |
| NCT00186589 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL | Lymphoma, Non-Hodgkin, Blood and Marrow Transplant (BMT) | P1 | Completed | 30 | Open-label | 90Y Ibritumomab tiuxetan |
| NCT02171208 A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers | Healthy | P1 | Completed | 80 | RCT, Double-blind | dimethyl fumarate - Reference form, dimethyl fumarate - Test form |
| NCT05216887 A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers | Healthy Volunteer | P1 | Completed | 123 | RCT, Open-label | Aducanumab |
| NCT06640933 A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy Participants | Healthy Volunteer | P1 | Completed | 25 | RCT, Open-label | BIIB091 |
| NCT04564612 Study of BIIB091 Formulations in Healthy Participants | Healthy Volunteers | P1 | Completed | 59 | Open-label | BIIB091, Rabeprazole, Itraconazole |
| NCT01598363 An Open-Label Study of the Effect of Bardoxolone Methyl on the Single Dose Pharmacokinetics of Digoxin and Rosuvastatin in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 32 | RCT, Open-label | Digoxin, Rosuvastatin |
| NCT01017198 Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 20 | RCT, Open-label | BIIB021 and Food, BIIB0121 and Antacid |
| NCT00674947 A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors | Solid Tumors | P1 | Completed | 55 | Open-label | BIIB015 |
| NCT01244139 Safety Study of BIIB033 in Subjects With Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | P1 | Completed | 47 | RCT, Double-blind | BIIB033, Placebo |
| NCT01119781 A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers | Healthy, Renal Insufficiency | P1 | Completed | 35 | Open-label | BIIB017(peginterferon beta-1a) |
| NCT02071121 Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect | Healthy | P1 | Completed | 39 | RCT, Double-blind | BIIB061, Placebo, 14C-BIIB061 |
| NCT03224793 Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects. | Healthy Subjects | P1 | Completed | 32 | RCT, Double-blind | BIIB059, Placebo |
| NCT00488566 GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers | Bipolar Disorder | P1 | Completed | 50 | RCT, Double-blind | GSK drug |
| NCT03626012 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | P1 | Completed | 106 | RCT, Double-blind | BIIB078, Placebo |
| NCT02228395 Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers | Healthy | P1 | Completed | 12 | RCT, Double-blind | PF-04958242, Placebo |
| NCT00526812 A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas | Glioma | P1 | Completed | 54 | Open-label | RTA 744, RTA 744 injection |
| NCT01632449 Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers. | Healthy Volunteers | P1 | Completed | 80 | RCT, Single-blind | Test product, Reference product |
| NCT01549769 Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes | Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2 | P1 | Terminated | 24 | Open-label | Bardoxolone Methyl |
| NCT02981082 Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension | Systemic Sclerosis, Pulmonary; Hypertension | P1 | Terminated | 6 | RCT, Double-blind | Dimethyl Fumarate (DMF), Placebo Oral Tablet |
| NCT00955396 Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure | Healthy Volunteer | P1 | Completed | 60 | RCT, Double-blind | GSK1014802, Placebo |
| NCT01924832 BG00012 Regional Absorption Study | Healthy | P1 | Completed | 32 | Open-label | dimethyl fumarate |
| NCT01052506 BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects | Healthy | P1 | Completed | 72 | RCT, Double-blind | BIIB033, Placebo |
| NCT01677572 Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease | Alzheimer's Disease | P1 | Terminated | 197 | RCT, Double-blind | Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb), Placebo |
| NCT04593121 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants | Healthy Volunteers | P1 | Completed | 84 | RCT, Double-blind | BIIB107, Placebo |
| NCT00956436 Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | P1 | Completed | 40 | Open-label | BIIB022, Sorafenib |
| NCT03056729 Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease | Alzheimer's Disease, Healthy Volunteer | P1 | Completed | 46 | RCT, Double-blind | BIIB076, Placebo |
| NCT01159483 First-in-Human Study of PF-04958242 in Healthy Volunteers | Healthy Volunteer | P1 | Completed | 24 | RCT, Double-blind | PF-04958242, Placebo |
| NCT03264079 Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy Adults | Healthy Volunteers | P1 | Completed | 16 | Open-label | Bardoxolone methyl capsules 10 mg, Itraconazole capsules 100 mg |
| NCT02106897 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus, Healthy Volunteers | P1 | Completed | 109 | RCT, Double-blind | BIIB059 (litifilimab), Placebo |
| NCT05927649 A TQTc Study for Omaveloxolone | Health Adult Subjects | P1 | Completed | 30 | RCT, Double-blind | Omaveloxolone, Moxifloxacin |
| NCT02052791 An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246) | Spinal Muscular Atrophy | P1 | Completed | 47 | Open-label | nusinersen |
| NCT00970580 A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | P1 | Completed | 18 | Open-label | BIIB022 With Paclitaxel and Carboplatin |
| NCT05152485 A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants | Healthy Volunteers | P1 | Completed | 36 | RCT, Open-label | BIIB104 Reference Formulation, BIIB104 Test Formulation |
| NCT02359344 PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers | Trigeminal Neuralgia | P1 | Completed | 32 | RCT, Double-blind | CNV1014802, Placebo |
| NCT01842126 Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin) | Painful Lumbar Radiculopathy, Healthy | P1 | Completed | 54 | RCT, Double-blind | BG00010 IV, BG00010 SC, Placebo IV, Placebo SC |
| NCT02555085 Single Ascending Doses of BIIB063 in Healthy Volunteers | Healthy | P1 | Terminated | 29 | RCT, Double-blind | BIIB063 |
| NCT01749098 A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers | Schizophrenia | P1 | Completed | 29 | RCT, Double-blind | PF-04958242, Ketamine, Placebo, Ketamine |
| NCT02332798 Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia | Schizophrenia | P1 | Completed | 39 | RCT, Double-blind | PF-04958242, Placebo |
| NCT01453426 Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers | Healthy | P1 | Completed | 71 | RCT, Open-label | BG00012 Dose 1, BG00012 Dose 2 |
| NCT01424163 Dexpramipexole Japanese PK Study | Amyotrophic Lateral Sclerosis | P1 | Completed | 57 | Open-label | Single dose reduced, Single dose standard, Multiple Dose, Multiple Dose |
| NCT00299962 Gene Therapy for Pleural Malignancies | Pleural Mesothelioma, Metastatic Pleural Effusions | P1 | Completed | 17 | Open-label | Adenoviral-mediated Interferon-beta, SCH 721015 |
| NCT04008186 A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone | Healthy Adult Subjects | P1 | Completed | 61 | Open-label | Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG, MetFORMIN 500 Mg Oral Tablet, Rosuvastatin, Digoxin tablet, Gemfibrozil Tablets, Itraconazole capsule, Verapamil Pill |
| NCT01461161 A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl | Healthy Volunteers | P1 | Completed | 32 | RCT, Double-blind | bardoxolone methyl |
| NCT07149415 A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55 | Healthy Volunteer | P1 | Completed | 22 | Open-label | Omaveloxolone, Omeprazole |
| NCT06262477 A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants | Healthy Volunteer | P1 | Completed | 300 | RCT, Double-blind | BIIB800, Actemra |
| NCT03943056 A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants | Healthy Volunteer | P1 | Completed | 64 | RCT, Double-blind | BIIB091, Placebo |
| NCT02228707 Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers | Healthy | P1 | Completed | 56 | RCT, Double-blind | BIIB061 |
| NCT05127564 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy Participants | Healthy Volunteers | P1 | Completed | 32 | Open-label | Diroximel fumarate |
| NCT02831517 PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants | Healthy, Trigeminal Neuralgia | P1 | Completed | 64 | RCT, Double-blind | BIIB074, Placebo |
| NCT02434718 Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease | Alzheimer's Disease | P1 | Completed | 21 | RCT, Double-blind | Aducanumab, Placebo |
| NCT00618735 Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 68 | Open-label | BIIB021, BIIB021 |
| NCT01500408 Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers | Multiple Sclerosis | P1 | Completed | 110 | RCT, Single-blind | Interferon beta-1a (current approved manufacturing process invloving FBS), Interferon beta-1a (new process, manufactured without FBS) |
| NCT01863069 Avonex®: Safety, Blood Levels and Effects | Multiple Sclerosis (MS) | P1 | Completed | 77 | RCT, Double-blind | Interferon beta 1a, (IM) AVONEX® |
| NCT01563562 Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function | Hepatic Impairment, Healthy | P1 | Completed | 34 | Open-label | Bardoxolone Methyl |
| NCT05148481 A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants | Healthy Volunteer | P1 | Completed | 31 | RCT, Double-blind | BIIB104, Placebo |
| NCT01365338 A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects | Healthy Volunteer | P1 | Completed | 112 | RCT, Double-blind | Placebo, PF-04958242 |
| NCT07019064 A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55 | Healthy Volunteer | P1 | Completed | 52 | RCT, Open-label | Omaveloxolone |
| NCT00858156 BG9928 in Subjects With Hepatic Impairment | Hepatic Impairment | P1 | Completed | 23 | Open-label | BG9928 |
| NCT02666963 A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults | Healthy | P1 | Completed | 78 | RCT, Double-blind | RTA 901 Capsules, 10 or 40 mg, Placebo |
| NCT00908154 Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802. | Bipolar Depression, Bipolar Disorder | P1 | Completed | 51 | RCT, Double-blind | Placebo, GSK1014802 |
| NCT00531193 Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers | Healthy | P1 | Completed | 32 | Open-label | BIIB014 |
| NCT06264440 A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants | Healthy Volunteer | P1 | Completed | 18 | Open-label | BIIB122, Rabeprazole |
| NCT01884935 PK and PD Study of Natalizumab in Pediatric Subjects With RRMS | Relapsing-Remitting Multiple Sclerosis | P1 | Completed | 13 | Open-label | Natalizumab |
| NCT00651443 Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma | Lymphoma, Non-Hodgkin's | P1 | Terminated | 20 | Open-label | Galiximab |
| NCT01069913 Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient | Healthy | P1 | Completed | 14 | RCT, Open-label | BG00012 |
| NCT02269930 Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers | Multiple Sclerosis | P1 | Completed | 30 | Open-label | peginterferon beta-1a, Rebif |
| NCT02698267 Effect of Itraconazole on the Pharmacokinetics of BIIB074 | Neuropathic Pain | P1 | Completed | 16 | Open-label | BIIB074, Itraconazole |
| NCT01035515 BIIB014 Cardiovascular Monitoring Study | Healthy | P1 | Completed | 24 | RCT, Double-blind | Placebo, BIIB014 50mg, BIIB014 100mg |
| NCT01313364 A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle | Healthy | P1 | Terminated | 80 | Open-label | — |
| NCT00345189 Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors | Tumors, Lymphoma | P1 | Completed | 70 | Open-label | CNF2024 |
| NCT03284931 A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model | Healthy | P1 | Completed | 45 | RCT, Double-blind | SAGE-217 high dose, Placebo, SAGE-217 low dose |
| NCT02551497 Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects | Healthy | P1 | Completed | 36 | RCT, Double-blind | CNV1014802 |
| NCT02460094 Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | P1 | Completed | 48 | RCT, Double-blind | BIIB092, Placebo |
| NCT00771329 BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Completed | 53 | RCT, Double-blind | BIIB023 |
| NCT01503866 A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects | Healthy | P1 | Completed | 6 | Open-label | bardoxolone methyl |
| NCT03324685 A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen | Drug Interactions | P1 | Completed | 36 | Open-label | BIIB074, OC (ethinyl estradiol and levonorgestrel) |
| NCT02951221 New Formulation and Food Effect Study of BIIB074 | Trigeminal Neuralgia (TN), Other Neuropathic Pain | P1 | Completed | 28 | RCT, Open-label | BIIB074 Treatment A, BIIB074 Treatment B, BIIB074 Treatment C, BIIB074 Treatment D |
| NCT01511510 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers | Schizophrenia | P1 | Completed | 39 | RCT, Double-blind | PF-04958242, PF-04958242, PF-04958242, PF-04958242, Placebo |
| NCT00913250 A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers | Multiple Sclerosis | P1 | Completed | 96 | RCT, Single-blind | Serum containing Avonex, Serum Free Avonex |
| NCT03385525 Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074 | Drug Interaction | P1 | Completed | 30 | Open-label | BIIB074, Valproic Acid |
| NCT00344786 Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL | B-Cell Chronic Lymphocytic Leukemia | P1 | Terminated | 15 | Open-label | CNF2024 (BIIB021) |
| NCT00412412 CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study | Breast Cancer | P1 | Completed | 34 | Open-label | CNF2024, CNF2024 + trastuzumab |
| NCT00529438 RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies | Advanced Solid Tumors, Lymphoid Malignancies | P1 | Completed | 47 | Open-label | Bardoxolone methyl |
| NCT01017666 BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam | Healthy | P1 | Completed | 28 | RCT, Double-blind | BIIB014, Placebo |
| NCT03664453 A Pharmacokinetic Study of Omaveloxolone in Healthy Volunteers | Healthy | P1 | Completed | 32 | RCT, Open-label | omaveloxolone |
| NCT00046488 Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia | P1 | Completed | 70 | RCT, Open-label | IDEC-152 |
| NCT02751905 Absorption, Metabolism, and Excretion Study of BIIB074 | Neuropathic Pain | P1 | Completed | 6 | Open-label | BIIB074 |
| NCT00837785 A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS | Relapsing Remitting Multiple Sclerosis | P1 | Completed | 48 | RCT, Open-label | BG00012, BG00012 |
| NCT02029716 RTA 408 Lotion in Healthy Volunteers | Healthy | P1 | Completed | 109 | RCT, Double-blind | RTA 408 Lotion 0.5%, 1%, 3%, Lotion vehicle/placebo |
| NCT04079101 Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants | Healthy Volunteers | P1 | Completed | 31 | RCT, Double-blind | BIIB104, Placebo |
| NCT01518920 A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss | Hearing Loss, Sensorineural | P1 | Completed | 44 | RCT, Double-blind | PF-04958242, PF-04958242, Placebo |
| NCT00105170 Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors | Tumors | P1 | Terminated | 13 | Open-label | hCBE-11 |
| NCT01407406 Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers | Healthy Volunteers | P1 | Completed | 48 | RCT, Double-blind | BIIB023 - low dose IV Dose, BIIB023 - high dose IV Dose |
| NCT01420458 Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012 | Healthy Volunteers | P1 | Completed | 80 | RCT, Open-label | Experimental |
| NCT02341482 A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects | Healthy | P1 | Completed | 13 | Open-label | PF-04958242, Itraconazole |
| NCT04068532 A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants | Healthy Volunteers | P1 | Completed | 30 | RCT, Double-blind | Placebo, BIIB104 |
| NCT00319930 Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL | Chronic Lymphocytic Leukemia | P1 | Terminated | 10 | Open-label | CNF1010 (17-AAG) |
| NCT04106050 Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy | Healthy Volunteers, Diabetic Neuropathies | P1 | Withdrawn | — | RCT, Double-blind | BIIB095, BIIB074, Placebo, Lidocaine |
| NCT01929746 Daclizumab Japanese PK Study | Healthy | P1 | Completed | 56 | RCT, Single-blind | BIIB019 subcutaneous injection |
| NCT06311786 A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants | Healthy Volunteer | P1 | Completed | 8 | Open-label | [14C]-BIIB091 |
| NCT00527410 A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis | Leptomeningeal Carcinomatosis | P1 | Terminated | 9 | Open-label | RTA 744 |
| NCT00964288 Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects | Pain, Neuropathic, Neuropathic Pain | P1 | Terminated | 16 | RCT, Double-blind | GSK1014802 low dose, Lidocaine, GSK1014802 high dose, Placebo |
| NCT03902002 A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function | Hepatic Impairment | P1 | Completed | 48 | Open-label | Omaveloxolone 50 mg capsules |
| NCT01405833 Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica. | Sciatica | P1 | Completed | 56 | RCT, Double-blind | BG00010 (Neublastin), Placebo |
| NCT05160558 A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3 | Spinocerebellar Ataxia Type 3 | P1 | Terminated | 8 | RCT, Double-blind | BIIB132, BIIB132-Matching Placebo |
| NCT02778438 A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits | Mild Cognitive Impairment, Alzheimer's Disease | Completed | 30 | — | — | |
| NCT05058950 An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging | Mild Cognitive Impairment, Normal Aging | Terminated | 22,720 | — | — | |
| NCT03554343 Sun May Arise on SMA : Newborn Screening of Spinal Muscular Atrophy in Belgium | Spinal Muscular Atrophy | Completed | 136,339 | — | — | |
| NCT01056848 International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430 | Hyponatremia With Normal Extracellular Fluid Volume, Hyponatremia With Excess Extracellular Fluid Volume | Completed | 135 | — | — | |
| NCT00443443 A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE) | Rheumatoid Arthritis | Completed | 1,026 | — | — | |
| NCT05260151 Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases | Alzheimer Disease, Progressive Supranuclear Palsy | Unknown | 155 | — | — | |
| NCT04288128 Integrated Functional Evaluation of the Cerebellum | Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 7 | Completed | 40 | — | — | |
| NCT04002492 Effects of a Weight Based Training Program on MS Patients | Multiple Sclerosis | N/A | Unknown | 25 | Open-label | — |
| NCT01065090 A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis | Exercise | Completed | 38 | — | — | |
| NCT02466529 Natural History of Spinal Muscular Atrophy Type 1 in Taiwan | Natural History of Type 1 Spinal Muscular Atrophy (SMA) | Completed | 111 | — | — | |
| NCT01911767 Biogen Multiple Sclerosis Pregnancy Exposure Registry | Multiple Sclerosis, Exposure During Pregnancy | Completed | 408 | — | Dimethyl fumarate, Peginterferon beta-1a | |
| NCT02776072 Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis | Completed | 2,978 | — | — | |
| NCT01070836 JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab | Relapsing Multiple Sclerosis | Completed | 35,895 | — | natalizumab | |
| NCT02969304 Study of Utilization Patterns of Dimethyl Fumarate in Germany | Multiple Sclerosis | Completed | 930 | — | dimethyl fumarate | |
| NCT00884481 Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS | Relapsing-Remitting Multiple Sclerosis, Fatigue | Completed | 195 | — | — | |
| NCT03300869 Natural History of Types 2 and 3 SMA in Taiwan | Spinal Muscular Atrophy | Unknown | 300 | — | — | |
| NCT02795897 Genomic Translation for Amyotrophic Lateral Sclerosis Care | ALS | Completed | 254 | — | — | |
| NCT01532154 Fampridine Pregnancy Exposure Registry | Multiple Sclerosis, Pregnancy | Terminated | 1 | — | Fampridine | |
| NCT04145284 Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS | Multiple Sclerosis | Completed | 6 | — | — | |
| NCT01518660 Multiple Sclerosis and Progressive Resistance Training | Multiple Sclerosis (Relapsing Remitting) | N/A | Completed | 35 | RCT, Open-label | — |
| NCT04580381 Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort | Multiple Sclerosis, Relapsing-Remitting | Completed | 500 | — | Natalizumab Injection [Tysabri] | |
| NCT01070823 JC-Virus (JCV) Antibody Program | Multiple Sclerosis | Completed | 1,096 | — | Tysabri® (natalizumab) | |
| NCT05446285 Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE | Relapsing Remitting Multiple Sclerosis | Unknown | 245 | — | — | |
| NCT05097131 An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US | Alzheimers Disease | Terminated | 29 | — | — | |
| NCT02369224 Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics | Multiple Sclerosis | Completed | 27 | — | — | |
| NCT02159573 Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) | Relapsing-Remitting Multiple Sclerosis | Completed | 530 | — | natalizumab, dimethyl fumarate | |
| NCT01945359 Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design | Relapsing Remitting Multiple Sclerosis | Completed | 30 | — | — | |
| NCT02644083 Tecfidera and MRI for Brain Energy in MS | Multiple Sclerosis | Terminated | 4 | — | Dimethyl fumarate | |
| NCT00492570 GER-009-06-AVX Early Therapy in Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Completed | 230 | — | — | |
| NCT02099370 Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients | Multiple Sclerosis | Completed | 34 | — | — | |
| NCT05109637 A Study to Assess the Clinical Validity of Konectom™ in Adults Living With Neuromuscular Disorders | Spinal Muscular Atrophy | N/A | Completed | 93 | Open-label | — |
| NCT03498625 Crohn's Disease Endoscopic REmission Definition in an Objective Way | CD | N/A | Completed | 240 | Open-label | — |
| NCT01211678 Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients | Arthritis, Rheumatoid | Completed | 301 | — | — | |
| NCT02677077 Clinical Disease Activity With Long Term Natalizumab Treatment | Relapsing-Remitting Multiple Sclerosis | Completed | 277 | — | natalizumab | |
| NCT01330498 Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical | Multiple Sclerosis | Completed | 229 | — | — | |
| NCT03399981 Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries | Progressive Multifocal Leukoencephalopathy | Completed | 80,327 | — | Tysabri | |
| NCT04419233 Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection | Muscular Atrophy, Spinal | Completed | 50 | — | Nusinersen Sodium Injection | |
| NCT06602921 The Effects of Nitrate, Caffeine, and Cold Exposure on Cardiovascular Function. | Nitrate, Caffeine | N/A | Completed | 24 | RCT, Double-blind | — |
| NCT02996084 MS PATHS Normative Sub-Study | Healthy Volunteer | Completed | 246 | — | — | |
| NCT00232193 Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS | Relapsing-remitting Multiple Sclerosis, Clinically Isolated Syndrome | Completed | 40 | — | — | |
| NCT00223457 Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis | Multiple Sclerosis | Completed | 1,040 | — | — | |
| NCT01405872 Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™. | Multiple Sclerosis | Completed | 270 | — | — | |
| NCT04746976 Study of Diroximel Fumarate in the Real-World Setting | Relapsing Forms of MS | Terminated | 75 | — | Diroximel Fumarate | |
| NCT04268147 Instrumented Data Exchange for Ataxia Study | Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2 | Completed | 128 | — | — | |
| NCT04599023 Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System | Multiple Sclerosis, Clinically Isolated Syndrome | Terminated | 182 | — | — | |
| NCT00818038 A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function | Relapsing-Remitting Multiple Sclerosis | Completed | 30 | — | BG0002 (natalizumab) | |
| NCT02531009 Systemic Sclerosis Clinical and Biomarker Study | Healthy, Systemic Sclerosis | Withdrawn | — | — | — | |
| NCT00618267 ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay. | Multiple Sclerosis | Completed | 100 | — | — | |
| NCT03327454 Benepali® PEN Patient Satisfaction Survey | Rheumatoid Arthritis, Spondyloarthropathies | Completed | 500 | — | Benepali | |
| NCT03100734 Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel | Rheumatoid Arthritis, Axial Spondyloarthritis | Completed | 585 | — | Benepali, Enbrel | |
| NCT03347370 A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Completed | 626 | — | SC Peginterferon beta-1a, SC interferon beta-1a, SC interferon beta-1b | |
| NCT03926637 Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis | Multiple Sclerosis | Terminated | 3,073 | — | — | |
| NCT01731054 Functional MRI in Lupus Nephritis | Healthy, Lupus Nephritis | Completed | 50 | — | — | |
| NCT03681015 Wearable Assessments in the Clinic and Home in PD | Parkinson Disease | Completed | 132 | — | — | |
| NCT00477113 TYSABRI Global Observational Program in Safety | Multiple Sclerosis | Completed | 2,207 | — | — | |
| NCT04948606 Exploring Diroximel Fumarate Real-world Experience in Canada and Israel | Relapsing Forms of MS | Terminated | 64 | — | Diroximel Fumarate | |
| NCT01592474 Evaluation of Brain Atrophy in CIS Patients on Avonex | Multiple Sclerosis | Completed | 180 | — | — | |
| NCT00464074 Evaluation of Natalizumab for thE Relief of MS Associated FatiGue | Multiple Sclerosis | Completed | 89 | — | — | |
| NCT04756700 Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis | Multiple Sclerosis | N/A | Completed | 158 | RCT, Open-label | — |
| NCT02440126 Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk | Multiple Sclerosis | Completed | 196 | — | — | |
| NCT05561621 Prediction of Non-motor Symptoms in Fully Ambulatory MS Patients Using Vocal Biomarkers | Multiple Sclerosis | Completed | 70 | — | — | |
| NCT02839460 A Prospective Study Of Biomarkers Of Skeletal Muscle Atrophy | Sarcopenia | Completed | 30 | — | — | |
| NCT05106465 A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage | Multiple Sclerosis (MS) | Completed | 200 | — | — | |
| NCT00483847 TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World | Multiple Sclerosis | Completed | 4,296 | — | — | |
| NCT02236624 Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis? | Multiple Sclerosis | N/A | Completed | 20 | Open-label | — |
| NCT00387023 Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma | Non-Hodgkin's Lymphoma, Lymphoma | N/A | Completed | 12 | Open-label | Rituximab, Zevalin |
| NCT02749396 EPID Multiple Sclerosis Pregnancy Study | Multiple Sclerosis | Completed | 2,089 | — | Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG, Extavia (interferon beta-1b), Novartis Pharma AG, Rebif (interferon beta-1a), Merck Serono Europe Ltd, Plegridy (peginterferon beta-1a), Biogen Idec Ltd, Avonex (interferon beta-1a), Biogen Idec Ltd, MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046) | |
| NCT01211639 Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy | Progressive Multifocal Leukoencephalopathy | Terminated | 24 | — | — | |
| NCT01156298 Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance | Multiple Sclerosis | Terminated | 383 | — | — | |
| NCT02519413 Tecfidera Lymphocyte Chart Review | Multiple Sclerosis | Completed | 483 | — | dimethyl fumarate | |
| NCT05197699 Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study | Multiple Sclerosis (MS) | Terminated | 160 | — | — | |
| NCT04089514 A Real-world Study of Imraldi® Use | Arthritis, Rheumatoid (RA), Axial Spondyloarthritis (axSpA) | Completed | 1,000 | — | Adalimumab | |
| NCT00168714 Pregnancy Exposure Registry for Avonex (Interferon Beta-1a) | Prenatal Exposure Delayed Effects, Multiple Sclerosis | Completed | 329 | — | BG9418 (interferon beta-1a) | |
| NCT00472992 Pregnancy Exposure Registry for Tysabri® | Crohn's Disease, Prenatal Exposure | Completed | 376 | — | — | |
| NCT02004444 JC Virus Reactivation in Multiple Sclerosis | Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis | Completed | 50 | — | — | |
| NCT01816100 The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients | Multiple Sclerosis | N/A | Completed | 6 | Open-label | — |
| NCT01749943 Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis | Multiple Sclerosis | Completed | 21 | — | — | |
| NCT00493298 Tysabri Observational Program | Relapsing-Remitting Multiple Sclerosis | Completed | 6,620 | — | Tysabri | |
| NCT01626248 Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control | Multiple Sclerosis | Completed | 164 | — | — | |
| NCT03593499 Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401 | Melanoma | NO_LONGER_AVAILABLE | — | — | omaveloxolone | |
| NCT00424788 A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS) | Relapsing Forms of Multiple Sclerosis | Early P1 | Completed | 12 | Open-label | natalizumab treatment |
| NCT01903291 Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS | Relapsing Forms of Multiple Sclerosis | Completed | 333 | — | dimethyl fumarate | |
| NCT02308657 Multicenter Observational Study of Myotonic Dystrophy Type 1 | Myotonic Dystrophy Type 1 | Completed | 120 | — | — | |
| NCT01070719 Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort | Multiple Sclerosis, Relapse | Completed | 270 | — | — | |
| NCT06127095 A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments | Multiple Sclerosis, Relapsing-Remitting | Completed | 474 | — | — | |
| NCT02125695 Pilot Tape Harvesting Study | Atopic Dermatitis, Healthy | Completed | 37 | — | — | |
| NCT01185717 JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) | Multiple Sclerosis | Completed | 7,726 | — | — | |
| NCT04591678 Adults With SMA Treated With Nusinersen | Spinal Muscular Atrophy | Completed | 15 | — | nusinersen | |
| NCT04924153 A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy | KCNT1-Related Epilepsy | Completed | 35 | — | — | |
| NCT05475691 Longitudinal Data Collection in Pediatric and Adult Patients With Spinal Muscular Atrophy in Latin America | Spinal Muscular Atrophy | Unknown | 361 | — | — | |
| NCT01335633 Psychometric Validation of Cognitive Endpoints | Multiple Sclerosis | Completed | 60 | — | — | |
| NCT01272128 Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study | Multiple Sclerosis | Completed | 100 | — | Interferon beta-1a | |
| NCT01485003 Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants | Relapsing-Remitting Multiple Sclerosis | Completed | 231 | — | natalizumab | |
| NCT06089018 Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic Dystrophy | Myotonic Dystrophy 1 | Unknown | 125 | — | — | |
| NCT05209815 Safety of Exposure to Natalizumab During Pregnancy | Multiple Sclerosis | Completed | 68 | — | — | |
| NCT03088956 Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD) | Frontotemporal Dementia, Behavioral Variant Frontotemporal Dementia | Completed | 47 | — | — | |
| NCT01641120 Assessing Tolerability of Avonex Intramuscular Injections | Multiple Sclerosis | N/A | Completed | 20 | Single-blind | Avonex |
| NCT00675883 COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS | Multiple Sclerosis, Relapsing-Remitting | Completed | 1,000 | — | — | |
| NCT03359551 Natural History of the Progression of Choroideremia Study | Choroideremia | Completed | 319 | — | — | |
| NCT01366040 Avonex PEN Satisfaction and Patients Experience Clinical Trial | Multiple Sclerosis | Completed | 89 | — | — | |
| NCT03487900 Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up | CD | N/A | Unknown | 320 | Open-label | — |
| NCT02686268 Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS | C9ORF72 Amyotrophic Lateral Sclerosis (ALS) | Completed | 128 | — | — | |
| NCT02283918 Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery | Healthy | Completed | 467 | — | — | |
| NCT00422617 Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients | Chronic Plaque Psoriasis | N/A | Completed | 40 | Open-label | Alefacept (Amevive) |
| NCT02611674 Methodology Study of Novel Outcome Measures to Assess Progression of ALS | Amyotrophic Lateral Sclerosis | Completed | 138 | — | — | |
| NCT00599274 Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis | Multiple Sclerosis | Completed | 136 | — | Interferon beta-1a, Interferon beta-1a | |
| NCT00288990 A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis | Multiple Sclerosis | Completed | 300 | — | — | |
| NCT04972487 Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis | Superoxide Dismutase 1-Amyotropic Lateral Sclerosis | APPROVED_FOR_MARKETING | — | — | Tofersen | |
| NCT04795206 Natural Disease Progression in Participants With Choroideremia | Choroideremia | Completed | 1,178 | — | — | |
| NCT04926129 Natural History of the Progression of X-Linked Retinitis Pigmentosa | X-Linked Retinitis Pigmentosa | Completed | 201 | — | — | |
| NCT04123353 Scan-Rescan Sub-Study of MS PATHS | Multiple Sclerosis | Completed | 30 | — | — | |
| NCT01071512 Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis | Multiple Sclerosis | N/A | Completed | 20 | Open-label | Tysabri |
| NCT04750785 A Study to Assess Choroideremia (CHM) Health Outcomes | Choroideremia | Completed | 46 | — | — | |
| NCT00463710 Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS | Multiple Sclerosis | Completed | 150 | — | Avonex® monotherapy (6.0 MIU administered i.m. each week) |